For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Metabolic Peptide
GLP-1 (S)
A long-acting GLP-1 receptor agonist with a 31-amino-acid backbone and a fatty-acid side chain for albumin binding, studied extensively in clinical research for metabolic regulation and body composition.
Size
Quantity
$42.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
GLP-1 (S)
1 × 3mg · $42.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
20mg
99.78%latest
| Tested | Measured | Purity |
|---|---|---|
| Dec 2025 | 22.70mg | 99.78% |
Frequently researched together
Commonly studied alongside GLP-1 (S).
Compound information
Technical specifications
Molecular profile
| Type | GLP-1 receptor agonist |
| CAS number | 250685-44-0 |
| Molecular weight | 4114 g/mol |
| Amino acids | 31 |
| Formula | C187H291N45O59 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- The lancet. Diabetes & endocrinology
Efficacy and safety of once-weekly GLP-1 (S) monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
2017·DOI: 10.1016/S2213-8587(17)30013-X·PMID: 28110911Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T
View source - Lancet (London, England)
GLP-1 (S) 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
2021·DOI: 10.1016/S0140-6736(21)00213-0·PMID: 33667417Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L
View source - Drugs
GLP-1 (S): First Global Approval
2018·DOI: 10.1007/s40265-018-0871-0·PMID: 29363040Dhillon S
View source - Trends in cardiovascular medicine
GLP-1 (S) for the treatment of obesity
2023·DOI: 10.1016/j.tcm.2021.12.008·PMID: 34942372Chao AM, Tronieri JS, Amaro A, Wadden TA
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.